Clinical Trial Update: Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of avapritinib with azacitidine and venetoclax for relapsed acute myeloid leukemia after allogeneic HSCT is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Avapritinib (avapritinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML (Acute Myelogenous Leukemia) | Phase 2 | Status: RECRUITING